Supernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on Tuesday

Supernus Pharmaceuticals (NASDAQ:SUPN) is expected to announce its earnings results after the market closes on Tuesday, February 25th. Analysts expect the company to announce earnings of $0.46 per share and revenue of $155.25 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Supernus Pharmaceuticals Stock Performance

SUPN stock opened at $33.05 on Friday. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of 30.89 and a beta of 0.90. Supernus Pharmaceuticals has a 1 year low of $25.53 and a 1 year high of $40.28. The stock’s fifty day moving average is $37.48 and its two-hundred day moving average is $35.36.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald cut shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $57.00 to $36.00 in a research note on Wednesday.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at $402,103.38. The trade was a 6.45 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 9.30% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.